OXFORDSHIRE, United Kingdom, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Midatech (AIM:MTPH), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, announces that today, 18 December 2015, Jim Phillips, Chief Executive Officer, purchased 960 ordinary shares of 0.005p each in the capital of the Company ("Ordinary Shares") at a price of 204 pence per Ordinary Share. Following this purchase, Mr. Phillips’ direct beneficial interest in the Company is 36,871 Ordinary Shares, representing 0.11% of the Company’s total issued share capital.
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech’s strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company’s R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com
For more information, please contact: Midatech Pharma PLC Jim Phillips, CEO Tel: +44 (0)1235 841575 www.midatechpharma.com Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) Corporate Finance Freddy Crossley / Atholl Tweedie / Duncan Monteith Broking Tom Salvesen Tel: +44 (0)20 7886 2500 RBC Europe Limited (Joint Broker) Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman Tel: +44 (0)207 653 4000 Consilium Strategic Communications (Financial PR) Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys Tel: +44 (0)20 3709 5700 Email: email@example.com